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Background/aim: Microsatellite instability tests and programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) in
the immune checkpoint pathway are the tests that determine who will benefit from immune checkpoint inhibitor therapy. We aimed
to show the expression of DNA mismatch repair proteins and PD-1/PD-L1 molecules that inhibit immune checkpoints, to explain the
relationship between them, and to demonstrate their predictive role in recurrent and nonrecurrent glioblastoma.
Materials and methods: We analyzed 27 recurrent and 47 nonrecurrent cases at our archive. We performed immunohistochemical
analysis to determine expressions of PD-1, PD-L1, and mismatch repair proteins in glioblastoma. We evaluated the relationship between
these two group and compared the results with the clinicopathological features.
Results: The mean age of diagnosis was significantly lower in recurrent glioblastoma patients. Median survival was longer in this
group. We found that PD-L1 expression was reduced in recurrent cases. Additionally, recurrent cases had a significantly higher rate of
microsatellite instability. Loss of PMS2 was high in both group but was substantially higher in recurrent cases.
Conclusion: The presence of microsatellite instability and low PD-L1 levels, which are among the causes of treatment resistance in
glioblastoma, were found to be compatible with the literature in our study, with higher rates in recurrent cases. In recurrent cases with
higher mutations and where immunotherapy resistance is expected less, low PD-L1 levels thought that different combinations with
other immune checkpoint inhibitors can be tried as predictive and prognostic marker in GBM patients.
Key words: Glioblastoma, mismatch repair, programmed cell death protein ligand 1 (PD-L1), programmed cell death protein 1 (PD-1),
microsatellite instability

1. Introduction
Glioblastoma (GBM) is the most common primary
brain tumor with a poor prognosis (47.1%) [1]. GBMs
are fatal tumors with a median survival time of 12
months. Approximately 3%–5% of cases live more than
3 years [2]. Many studies are showing the importance of
genetic susceptibility, exogenous factors, age and clinical
parameters at the time of diagnosis, as the reason for
aggressive behavior [3–6]. Other important factors are
surgical procedures and multimodal treatment options.
Immunotherapy is a promising treatment method that
shows a synergistic effect with radiotherapy [7].
Immune checkpoints can be grouped into two main
groups as immunostimulating and blocking. The main
molecules that inhibit immune checkpoints are the
cytotoxic t-lymphocyte-associated protein-4 (CTLA-4),
programmed death-1 (PD-1) receptor, and its two ligands
(PD-L1 and PD-L2). These molecules block control signals

that lead to the T cell response against the tumor. New
treatments are aimed at inhibiting PD-L1 on the tumor
cell or PD-1 receptor on the T cell which will produce an
antitumoral response. These treatment agents are called
immune checkpoint inhibitors (ICIs). CTLA-4, one of
the major inhibitory molecules in GBMs, is released from
T cells, binding to its ligands (CD80, CD86) reduces
the activation and proliferation of effector T cells and
increases the activation of regulatory T cells (Treg) in the
GBM microenvironment [8,9].
PD-1 is released from T cells and other immune cells.
One of its ligands, PD-L1 is found in Tregs in the GBM
microenvironment, tumor-associated macrophages, and
other cells in the tumor microenvironment, including
tumor cells [8,10]. The predictive markers in PD-1/PDL1 antibody therapy are mainly the number of cytotoxic
T-lymphocytes inside tumor tissues and the expression
level of PD-L1 in cancer cells [11,12]. In extensive studies,
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PD-L1 expression levels in GBMs were found between
61%–88% [13–15]. High PD-L1 mRNA expression level
was found to be associated with shorter overall survival in
glioma patients [12,16,17].
Treating recurrent GBMs is more difficult and
resistance develops more frequently to treatment. These
tumors have been treated several times (radiotherapy and
temozolomide) and therefore contain a greater number
of mutations. Due to the presence of potential new
antigens, these tumors are assumed to be more suitable
for the recognition and attack of the immune system. In
contrast to the hypothesis that the tumor assumes that it
will increase the release of PD-L1 with the immune-escape
mechanism developed to protect itself from stronger
immune response, in some studies, this rate was found to
be significantly lower in recurrent tumors [13,14,18].
PD-1/PD-L1 expression, tumor mutation load, and
DNA mismatch repair (MMR) defects are thought to be
related to the treatment response. Some clinical studies
revealed that defective MMR is associated with clinical
responses to immune checkpoint inhibitors (ICI) [5,19].
Tumors with high microsatellite instability (MSI) and high
immunogenicity benefit from immunotherapy more and
have a better clinical course. Therefore, it is recommended
to use MSI status as a marker for response to PD-1/PD-L1
blockade in cancer patients [20].
In the last 6 years, significant results have been obtained
in immunotherapy in various tumors (melanoma, renal
cell cancer, lung cancer, head, and neck cancers) with
anti-PD-1/PD-L1 antibodies. While the response to PD-1
inhibitors is significantly high in lymphoma subtypes
(87% in Hodgkin’s lymphoma), this rate ranges from
15% to 40% in solid organ cancers [21,22]. There are
several studies showing that PD-1 inhibition increases
the antitumor responses and survival rate on animal
glioma models [23,15]. Especially combined immune
checkpoint blockade resulted in 100% long survivors [23].
However, there is insufficient clinical evidence to support
its effectiveness in GBM patients. There are some “case
reports” in the literature showing that anti-PD-1 therapy
(nivolumab) have significant therapeutic effects on GBM
patients [19,24,25].
2. Material and methods
2.1 Patients and clinical information
In our study, 74 cases (recurrent and nonrecurrent GBM)
diagnosed in our department between 2007–2019 were
selected. Twenty-seven of these cases showed recurrence.
Hypercellular tumors including palisading necrosis
and vascular endothelial proliferation were accepted as
‘original tumor’. Diffuse necrosis, vascular hyalinization,
gliosis, and the presence of rare atypical cells were
accepted as ‘radiotherapy effect’. High-grade glioma with

mitosis and minimal evidence of radiation effect is defined
as ‘recurrent tumor’ [26]. The first resection materials of
the recurrent cases were defined as “Group 1”, the 2nd
resection materials were “Group 2” and the nonrecurrent
cases were defined as “Group 3”. When calculating rates
in recurrent cases, cases were considered “positive” if any
of the cases in group 1 or 2 were positive. The results of
recurrent and nonrecurrent GBM patients were compared.
In addition, in recurrent cases, the expression rates in
the 1st and 2nd resection materials were compared. For
each case, the patient’s age at the time of diagnosis, sex,
time for recurrence, and survival were recorded. Clinical
information was obtained from patient files on the
computer.
2.2 Immunohistochemical study
Immunohistochemically, the relationship between MLH1
(MutL Homolog 1), MSH2 (MutS Homolog 2), MSH6
(MutS Homolog 6), and PMS2 (PostMeiotic Segregation
increased 2) results and immune checkpoint inhibitors
PD-1 and PD-L1 were examined and compared with
the clinicopathological features. Sections stained with
immunohistochemical antibodies were examined under
a light microscope (Olympus BX50). Normal colon tissue
was used as a control of the immunohistochemical MLH1,
MSH2, MSH6, and PMS2 markers. Expressions of MMR
proteins were evaluated as follows: Nuclear staining in
more than 80% neoplastic cells was accepted as score 4;
51%–80% staining score 3; 10%–50% staining score 2;
less than 10% staining score 1 and no nuclear staining
score 0 [27]. Expressions of MMR proteins were shown in
Figure 1 (Figure 1: a) Loss of nuclear staining with MLH1
(×200), b) Nuclear staining with MLH1 (×100), c) Loss of
nuclear staining with MSH2 (×200), d) Nuclear staining
with MSH2 (×100), e) Loss of nuclear staining with MSH6
(×200), f) Nuclear staining with with MSH6 (×200),
g) Loss of nuclear staining with with PMS2 (×100), and
h) Nuclear staining with PMS2 (×100)). Loss of nuclear
expression of one or more MMR proteins was accepted as
deficient mismatch repair [28].
SP263 clone of the PD-L1 antibody was used. Diffuse
fibrillar/membranous staining in tumor tissue was
evaluated. According to previous studies, no staining
in nonnecrotic tumor tissue was accepted as score 0;
<25% staining score 1; 25%–50% staining score 2; 50%–
75% staining score 3 and > 75% staining score 4 [13].
Membranous staining in epitheloid tumor cells was
defined as (+) if > 5% staining in tumor cells as in previous
studies [13].
PD-1 expression was seen in lymphocytes in tumor
tissue, and perivascular space. It was scored as sparsely,
moderately and intensively according to the staining rates
in large magnification (200×–400×). The staining patterns
of PD-L1 and PD-1 were shown in Figure 2 (Figure 2: a)
Diffuse fibrillary PD-L1 staining in tumor matrix (×200),
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Figure 1. Expressions of MMR proteins.

b) Membranous PD-L1 staining on tumor cells (×400), c)
Diffuse fibrillary and membranous PD-L1 staining (×200),
d) PD-1 staining on tumor infiltrating lymphocytes
(×400)).
2.3 Statistical analysis
Descriptive analyses of the study group were given as
numbers and percentages. SPSS Statistics v: 22.0 (IBM SPSS,
2013, Armonk, NY, USA) was used for statistical analysis.
Comparisons between recurrent and nonrecurrent cases
were made using the Chi-square and Fisher’s Exact test,
and the comparison of the Group 1 and Group 2 with
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the Mc Nemar test. The mean and standard deviation
values were compared with student t test. In all analyses,
the statistical significance level was taken as p = 0.05. The
effects of recurrence, PD-L1 expression, MMR status, and
loss of PMS2 on survival in patients were examined using
log-rank test. Survival rates were calculated using the
Kaplan–Meier survival analysis.
3. Results
Of the 74 GBM patients, 29 (39.2%) were female and
45 (60.8%) were male with a median age of 58.4 (range,
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4–85). However, the mean age of diagnosis in recurrent
cases was 52.1 (4–75) and 62.1 (42–85) in nonrecurrent
cases and was significantly lower in recurrent GBM cases
(p = 0.007). Twenty-seven cases (36.5%) recurred, 62
cases (83.8%) died, and 12 cases (25.5%) are still alive. The
mean recurrence time was 8.2 months (0.8–39.7). Median
survival was 9.9 months (6.1–13.8) in all cases from the
time of diagnosis, and 12.5 months in recurrent cases; 6
months for nonrecurrent ones. The clinicopathological
characteristics of the patients are given in Table 1.
On immunohistochemical study, PD-L1 expression
was observed in 36 (48.6%) of the 74 cases. Expression was
detected in 12 (44.5%) of the recurrent cases and 24 (51.0%)
of the nonrecurrent cases. Median survival was 7.1 months
in patients with PD-L1 (+) and 10 months in patients with
PD-L1(-). The effect of PD-L1 expression on survival was

not significant (p = 0.300), shown in Figure 3 (Figure 3:
a) Recurrent cases b) Nonrecurrent cases c) All cases).
Thirteen (17.6%) patients exhibited loss of expression for
at least one MMR protein and they were considered to
MSI. Nine of the cases with MSI were recurrent (33.3%)
and 4 were nonrecurrent GBM (8.5%). The details of the
immunohistochemical expression of MMR proteins are
given in Tables 2 and 3. Median survival for tumors with MSI
was 7 months, and 10 months for those with MSS. However,
MMR status did not have a significant effect on survival
(p = 0.953). Among the MMR proteins, loss of PMS2 was
noted in 9 recurrent cases (33.3%) and in 4 nonrecurrent
cases (8.5%). Median survival was 7 months in patients with
PMS2 loss and 10 months in patients without loss. However,
there was no significant effect of PMS2 loss on survival (p =
0.953). Loss of PMS2 was found to be significantly effective

Figure 2. The staining patterns of PD-L1 and PD-1.
Table 1. The clinicopathological characteristics of the recurrent and nonrecurrent cases.
Clinical parameters

Recurrent cases
(n = 27)

Nonrecurrent cases
(n = 47)

Total
(n = 74)

Sex (female/male) n (%)

11 (40.7)/16 (59.3)

18 (38.3)/29 (61.7)

29 (39.2)/45 (60.8)

Mean age (± SD)

52.1 (± 15.349)

62.1 (± 10.693)

58.4 (± 13.392)

Mean recurrence time (month) (95% CI)

8.2 (0.8–39.7)

-

-

Median survival time (month) (95% CI)

12.5 (7.4–17.5)

6.0 (3.7–8.2)

9.9 (6.1–13.8)

Death n (%)

27 (100)

35 (74.5)

62 (83.8)

Student t test: p = 0.02.
Median survival time: Kaplan–Meier.
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Figure 3. The effect of PD-L1 expression on survival.

in relapsed cases (p = 0.003). The median recurrence time
was 10.1 months in those with PMS2 loss, and 39.7 months
in those without. PD-1 expression was observed in 6 cases
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(8.1%). It was observed in 3 recurrent cases (11.1%) and 3
nonrecurrent cases (6.3%). The expressions of PD-L1, PD-1
and presence of MSI are given in Table 4.
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Table 2. Loss of MMR proteins in the recurrent cases (n = 27, p
< 0.05).
MMR proteins
MLH1
MSH2
MSH6
PMS2

Resection material

n

%

1st resection

1

3.7

2nd resection

0

0

1st resection

0

0

2nd resection

0

0

1st resection

0

0

2nd resection

2

7.4

1st resection

5

18.5

2nd resection

6

22.2

Table 4. The expressions of PD-L1, PD-1, and presence of MSI in
the recurrent and non-recurrent cases (n = 74, p < 0.05).

p

Protein expression

-

PD-L1

-

PD-1

-

MSI

1.000

MMR: Mismatch repair.
McNemar Exact test.

Cases

n

%

Recurrent

12

44.5

Nonrecurrent

24

51.0

Recurrent

3

11.1

Nonrecurrent

3

6.4

Recurrent

9

33.3

Nonrecurrent

4

8.5

p
0.060
0.536
0.011*

MSI: Microsatellite instability.
*Statistically significant.
Chi-Square Fisher’s Exact test.

Table 3. Loss of MMR proteins in all cases (n = 74, p < 0.05).
MMR proteins
MLH1
MSH2
MSH6
PMS2

Cases

n

%

Recurrent

1

3.7

Nonrecurrent

1

2.1

Recurrent

0

0

Nonrecurrent

0

0

Recurrent

2

7.4

Nonrecurrent

2

4.3

Recurrent

9

33.3

Nonrecurrent

4

8.5

p
0.635
0.530
0.011*

MMR: Mismatch repair.
*Statistically significant.
Chi-Square Fisher’s Exact test.

Figure 4. The relationship between MMR status and PD-L1
expression in recurrent and nonrecurrent GBM

Clinical features of Group 1 and 2 (recurrent) cases:
11 (40.7%) were female and 16 (59.3%) were male with
the median age was 52.1 (range, 4–75). All of them died.
The number of cases with PD-L1 (+) in Group 1 was 8
(29.6%). MSI was detected in 6 of 27 cases (22.2%). The
number of the cases with PD-1 (+) in Group 1 was 1
(3.7%). Loss of PMS2 was observed in 5 cases (18.5%).
The number of cases with PD-L1 (+) in Group 2 was 8
(29.6%), of which 4 were the same cases in Group 1. MSI
was detected in 6 of 27 cases (22.2%). Three of these cases
were the same as Group 1. The number of cases with PD-1
(+) was 2 (7.4%), both cases were different from Group 1.
Six cases had PMS2 loss (22.2%). Two cases were the same
as Group 1 and PMS2 loss was observed in 9 cases totally.
Clinical characteristics of Group 3 cases: 18 (38.3%) were

women and 29 (61.7%) were men with the median age
was 62.1 (42–85). Thirty five cases (74.5%) died and 12
cases (25.5%) are still alive.
The relationship between MMR status and PD-L1
expression in recurrent and nonrecurrent cases was
shown in Figure 4 (p = 0.448 and p = 0.348, respectively,
Chi-square Fisher’s exact test). There was no significant
difference between PMS2 and PD-L1 expression in
patients with or without recurrence (p = 1.000 and p =
0.348, respectively, Chi-square Fisher’s exact test). There
was no significant difference between PD-L1 expression
and survival in patients with or without recurrence (p =
0.136, log rank (Mantel Cox) test). There was no significant
difference between MMR status and survival in patients
with or without recurrence (p = 0.133, log rank (Mantel
Cox) test). There was no significant difference between
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loss of PMS2 and survival in patients with or without
recurrence (p = 0.133, log rank (Mantel Cox) test).
4. Discussion
The ability of GBM to cause local and systemic
immunosuppression limits the innate defense and adaptive
immunotherapy effect against the tumor, and thus
prevents the development of new therapies. The process
of immunosuppression is not only related to abnormal
PD-L1 expression in GBM cells, but also to the tumor
microenvironment.
In one of the most recent studies to elucidate
immunotherapy resistance mechanisms in GBM, it was seen
that low PD-L1 expression, low tumor mutation burden and
T lymphocytes, which are largely depleted in the tumor, are
indicators of decreased antitumor immunity [21].
However, PD-L1 expression levels are observed in
a highly variable range in GBMs. Although it was seen
between 61% and 88% in two studies with large patient
groups, the median percentage of PD-L1 expression on
tumor cells in the study of Nudom et al. was 2.7% [13–15].
Berghof et al. said that the rate of PD-L1-positive cases in
GBM was quite higher (72% in recurrent; 88% in newly
diagnosed GBM) than melanoma cases (30%) and nonsmall
cell lung cancer cases (25%–36%) [13]. In recurrent GBM
cases with higher mutations and where immunotherapy
resistance is expected less, we also found PD-L1 expression
lower than those which are nonrecurrent (44.5% and 51.0%,
respectively), similar to the studies of Berghof, Heynckes,
and Ndom [13,14,18].
While low PD-L1 expression levels are associated with
treatment resistance, some studies have shown that high
PD-L1 levels are associated with shorter overall survival in
glioma patients [12,17,29]. On the other hand, in several
other studies no significant relationship was found between
PD-L1 expression and survival [12,13,16,30]. In our
study, no significant difference was found between PD-L1
expression level and survival.
In tumors with deficient MMR, 10 to 100 times more
somatic mutations were found compared to those which
are proficient [21,31]. Microsatellite instability is not
high in GBM. Patients with MSI are generally young and
have colorectal cancer at the same time [32]. In a study
conducted with 30 different tumors, it was stated that the
neontigen burden in GBM was in the lower third section
[21,33]. In GBM, mutations in MMR genes are thought to
be associated with resistance to therapy and thus tumor
recurrence [8]. Martine et al. observed that the presence
of MSI was at a significantly higher rate in patients with
recurrent GBM and stated that this may be associated with
malignant progression [34]. We have also found the rate
of MSI significantly higher in recurrent patients than the
nonrecurrent ones (33.3%, and 8.5% respectively).
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GBM specimens containing MSH6 mutations have
been described as hypermutator phenotypes [35,36].
Shinsato et al. found reduced levels of MLH1 and PMS2
related to therapy resistance and recurrence [37]. We have
also found a significant elevation in PMS2 loss in all groups
(Table 2–3). PMS2 loss, which was observed more clearly
in recurrent cases, suggested that this change might be a
marker for malignant progression. However, we could not
find a significant relationship between the loss of PMS2
neither with survival nor PD-L1 expression.
In one of the studies on the role of the status of MSI
in predicting immunotherapy response, it was observed
that colorectal cancers with MMR deficiency had a high
response to PD-1 inhibitor therapy [30]. In another study,
the research was expanded and the effectiveness of PD-1
blockade was evaluated in 12 different tumor types with
MMR deficiency at an advanced stage and it was seen that
21% of the patients had a complete response and 53% of
the patients had an an objective radiological response [38].
In high-grade urothelial carcinomas, it was shown that
MMR deficiency (loss of MSH2 and MSH6) is associated
with increased PD-L1 expression [8,39]. PD-L1 and PD-L1
expressions were found high in colorectal and endometrial
cancers with microsatellite instability (MSI) [8,40].
In conclusion, MMR status is suggested as a marker for
response to PD-1/PD-L1 blockade in other cancer types.
However, we found that PD-L1 expression was low and
MSI rate was higher in recurrent GBM than nonrecurrent
cases and we could not find a significant relationship
between these two entities. The presence of higher
MSI in the patients with recurrent GBM in this study
indicates the importance of these proteins as a predictive
markers. However, low PD-L1 expression levels suggest
that this antibody may not be a good predictive marker
for determining the group of patients who will receive
immunotherapy.
In recent years, an increasing number of clinical
trials are available to try different combinations in GBM
treatment. We also think that different combinations with
other immune checkpoint proteins can be tried in GBM
patients to determine both prognostic and therapeutic
efficacy.
The limitation of our study was that the clinical data
about treatment modalities are incomplete and, therefore,
were not included in the article.
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